Actively Recruiting
Evaluating the Use of FreeStyle Libre 3 Continuous Glucose Monitoring to Support Adherence to GLP-1 and Dual GLP-1GIP Medications in Adults with Type 2 Diabetes
Led by Abbott Diabetes Care · Updated on 2026-10-27
800
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether the FreeStyle Libre 3 Continuous Glucose Monitoring System FSL3 can help people with type 2 diabetes stay on their glucagon-like peptide 1 GLP-1 or dual GLP-1glucose-dependent insulinotropic polypeptide GIP medication longer. The study involves adults with type 2 diabetes who are starting these medications for the first time. The goal is to see if using the FSL3 device improves adherence compared to standard care. Participants will be randomly assigned to either use the FSL3 system or continue with their existing standard of care to manage their diabetes. Those using the FSL3 will wear a sensor on the back of the upper arm that collects glucose readings via a paired smartphone. All subjects will begin their prescribed GLP-1 or GLP-1GIP medications following their healthcare providers instructions and will be titrated to the maximum tolerable dose during the study. The study lasts about 210 days for each participant. During this time, researchers will monitor how long participants remain on their GLP-1 or combination GLP-1GIP drugs. Participants will provide venous blood samples to test their HbA1c levels. They will be asked to follow study instructions, attend all visits, and use either the FSL3 system or their usual care devices to manage their diabetes. The main outcome measured is the duration of adherence to the prescribed medication.
CONDITIONS
Brief Title
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
Research Team
M
Mohamed Mohamed Nada, PhD
S
Shridhara Karinka, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here